Canada - Press Releases

SANTA CLARA, Calif., 17 mars 2025 /PRNewswire/ -- xTool, leader dans le domaine de la gravure laser, a annonc son dveloppement avec l'imprimante Apparel Printer sur Kickstarter. La campagne a atteint son objectif de financement en une heure et demie et a dpass le million de dollars. l'heure actuelle, l'imprimante sur textile xTool Apparel Printer a recueilli environ 4 millions de dollars auprs de plus de 689 bailleurs de fonds. Cette rponse marque l'entre russie de la marque dans le secteur de l'impression directe sur film (DTF).

Leading addiction treatment provider teams up with hometown Eagles to promote mental health awareness and substance use disorder treatment

ASHA Shares Advice for Safe(r) Cheering During the NCAA Tournament

NEW YORK, March 17, 2025 /PRNewswire/ -- Globant (NYSE: GLOB), a digitally native company focused on reinventing businesses through innovative technology solutions, launched the new Team Content Delivery System for the 2025 Formula 1 season during the Formula 1 Louis Vuitton Australian Grand Prix 2025, which occurred in Melbourne over the weekend. This cutting-edge development enhances the competitive experience of a sport that challenges race teams to perform at their highest potential.

NEW YORK, March 17, 2025 /PRNewswire/ -- Globant (NYSE: GLOB), a digitally native company focused on reinventing businesses through innovative technology solutions, launched the new Team Content Delivery System for the 2025 Formula 1 season during the Formula 1 Louis Vuitton Australian Grand Prix 2025, which occurred in Melbourne over the weekend. This cutting-edge development enhances the competitive experience of a sport that challenges race teams to perform at their highest potential.

SINGAPORE, March 17, 2025 /PRNewswire/ -- PT Bank Rakyat Indonesia (Persero) Tbk (IDX: BBRI) has once again achieved remarkable international recognition by securing five global awards at the Retail Banker International (RBI) Asia Trailblazer Awards 2025. The prestigious event, held in Singapore, was attended by BRI's President Director Sunarso, Director of Commercial, Small, and Medium Business Amam Sukriyanto, and Corporate Secretary Agustya Hendy Bernadi, who were present to receive the awards.

NAIROBI, Kenya, March 17, 2025 /PRNewswire/ --Huawei, UNESCO, and government partners officially announced the completion of Phase II of the Kenya DigiSchool Connectivity Project, which connected 21 schools to the Internet, including 6 schools for children with special educational needs.

NAIROBI, Kenya, March 17, 2025 /PRNewswire/ --Huawei, UNESCO, and government partners officially announced the completion of Phase II of the Kenya DigiSchool Connectivity Project, which connected 21 schools to the Internet, including 6 schools for children with special educational needs.

SHANGHAI, March 17, 2025 /PRNewswire/ --Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) forRN0361-an APOC3 targeted siRNA(small interfering RNA) therapeutic for severe hypertriglyceridemia (SHTG), mixed dyslipidemia, and familial chylomicronemia syndrome (FCS) treatment. The company plans to advance RN0361 development in HTG patients based on a favorable safety profile and sustained triglyceride (TG) reduction in a 6-month single dose phase 1 clinical trial. The upcoming randomized, double-blind, placebo controlled, multicenter global Ph2 study will evaluate RN0361 efficacy, safety and duration in hypertriglyceridemia patient population for nine-month follow-up period.

SHANGHAI, March 17, 2025 /PRNewswire/ --Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) forRN0361-an APOC3 targeted siRNA (small interfering RNA) therapeutic for severe hypertriglyceridemia (SHTG), mixed dyslipidemia, and familial chylomicronemia syndrome (FCS) treatment. The company plans to advance RN0361 development in HTG patients based on a favorable safety profile and sustained triglyceride (TG) reduction in a 6-month single dose phase 1 clinical trial. The upcoming randomized, double-blind, placebo controlled, multicenter global Ph2 study will evaluate RN0361 efficacy, safety and duration in hypertriglyceridemia patient population for nine-month follow-up period.

ATLANTA, March 17, 2025 /PRNewswire/ -- Piedmont is pleased to announce that Walter J. "Wally" Curran, Jr., M.D., FACR, FASCO has been named the Whitaker Endowed Chief of Piedmont Oncology. This bestowed title is supported by the Piedmont Foundation's Whitaker Endowment, a fund created by the Atlanta community in tribute to Piedmont's legendary cancer surgical leader, Dr. William Whitaker. This bestowal reflects Dr. Curran's exceptional contributions to leading real change in oncology care across Georgia.

ALBANY, N.Y., March 17, 2025 /PRNewswire/ -- Blumberg, a century-old pioneer in legal solutions, and Attorneys Corporation Service, Inc. (ACS), a respected industry leader, have announced their merger. This strategic union brings together two iconic brands with a shared commitment to excellence and innovation.

Well over 1 million homes are available to buyers, the most for this season in five years

New London base to enable greater access to innovative breast reconstruction and augmentation solutions for UK patients

SAN FRANCISCO and LOS ANGELES, March 17, 2025 /PRNewswire/ -- Alife Health (Alife), a leading provider of AI-powered tools to advance the in-vitro fertilization (IVF) process, is excited to expand its partnership with US Fertility, the nation's largest partnership of physician-owned fertility practices. In a move set to reshape the industry, US Fertility and Alife will provide each patient with her personalized, AI-driven IVF laboratory summary report, including embryo images, laboratory-generated grading, clinical significance, and next steps. This is a landmark in the integration of AI technology into reproductive healthcare. Further, it solidifies US Fertility's leadership in innovation and Alife's position as the go-to provider of AI-powered solutions for IVF.

Award-winning nonprofit organization providing children and adults with special needs the opportunity to experience the joy and camaraderie of baseball kicks off season March 18th - March 22nd.

The Association of Related Churches (ARC) announces new episodes of UNSCRIPTED with Dino Rizzo, featuring real conversations with impactful church leaders.

SAN JOSE, Calif., March 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and Chief Executive Officer, Dr. Amit Kumar, will be presenting at the 2025 Cancer Advocacy Group of Louisiana ("CAGLA") NeauxCancer Conference taking place on March 27-29, 2025 at the The Roosevelt Hotel in New Orleans.

Bracco Diagnostics Inc. (PRNewsFoto/Bracco Diagnostics Inc.) (PRNewsfoto/Bracco Group) HeartSee Logo

NEW YORK, March 17, 2025 /PRNewswire/ --GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for its investigational drug,radiprodil, for the treatment of GRIN-related neurodevelopmental disorder (NDD). Radiprodil is designed as a potent negative allosteric modulator selectively targeting the N-methyl-D-aspartate receptor subtype 2B (NR2B or GluN2B). The company is on track to initiate a pivotal Phase 3 trial for radiprodil in mid-2025 for the treatment of GRIN-related NDD with GoF mutations and has an ongoing global open-label clinical trial of radiprodil for the treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II.

Seven abstracts highlight long-term effects, consistent safety profile,and delayed disease progression with givinostat

- REDUCE 1 is a study running in parallel with REDUCE 2 to evaluate AR882's efficacy in lowering serum urate (sUA) levels in gout patients -

WILMINGTON, Del., March 17, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2024, and provided a business update.

CAMBRIDGE, United Kingdom, March 17, 2025 /PRNewswire/ --IgniteData has announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and Cambridge University Hospitals NHS Foundation Trust (CUH) to launch its Archer tool for clinical data integration in an ongoing Phase 3 study sponsored by AstraZeneca. This collaboration marks a significant milestone in IgniteData's aim of transforming clinical trials through automation and digital innovation.

PRODIA SPORT -- ONE BUR. COMPLETE PROCEDURE.